CVS Health shares rose 3.2% in pre-open trading following a second-quarter report that exceeded analyst forecasts on both earnings and revenue. Adjusted earnings per share came in at $2.58, topping the $1.85 consensus, while revenue reached $106.1 billion versus the $100.03 billion analysts had expected - a 7.3% increase from the year-ago quarter.
Management revised its full-year 2026 adjusted EPS guidance sharply upward to a range of $7.90 to $8.10, up from the prior $7.30 to $7.50 outlook and above the $7.45 analyst consensus. The company also raised its revenue guidance for the year to at least $414 billion.
A notable contributor to the quarter's outperformance was the Aetna health insurance business. The medical loss ratio improved to 87.4% from 89.9% a year earlier, reflecting tighter cost controls cited by management - a development investors had been monitoring closely as an indicator of margin recovery.
Adjusted operating income increased approximately 35.5% year-over-year to about $5.15 billion, another metric that came in ahead of expectations and supported the stronger bottom-line results.
Separately, CVS announced a new collaboration with Eli Lilly to make the GLP-1 weight-loss therapies Zepbound and Foundayo available through the CVS Health app with transparent pricing, and for same-day pickup at roughly 9,000 pharmacy locations. The move positions CVS to participate directly in distribution of these therapies through its retail and digital channels.
The broader U.S. equity market provided a modestly positive backdrop on the session, with the S&P 500 up 0.4%, the Dow Jones up 0.4%, and the Nasdaq up 0.2%. However, the scale of CVS's gain was driven primarily by company-specific results and announcements rather than macro market momentum.
Prior to the quarterly disclosure, several Wall Street firms - including UBS, Goldman Sachs, Bank of America, and RBC Capital - had maintained bullish stances on the stock and ratcheted up price targets into the $110 to $122 range, a reflection of growing confidence in the company's turnaround efforts.
Taken together, the sixth consecutive quarterly beat, the materially higher profit outlook, continued improvement in Aetna margins, and the high-profile GLP-1 distribution partnership combined to push CVS shares higher in pre-market trading. These developments reinforced a narrative that the company is executing on its integrated-care strategy across insurance, pharmacy and retail channels.
Context and implications
The quarter's results highlight margin recovery in the insurance segment and stronger operating profit metrics, while the Eli Lilly collaboration signals a strategic move to integrate prescription distribution and digital pricing transparency at scale across CVS's pharmacy footprint.